NEW YORK (GenomeWeb News) – BGI-Shenzhen today said that it has extended its offer to acquire Complete Genomics for $3.15 per share.

The offer, with a total deal value of nearly $118 million, was scheduled to expire at midnight tonight, New York City time. It has now been extended to midnight on Wednesday, Nov. 21.

According to BGI, as of the close of business yesterday, approximately 6,731,897 shares had been validly tendered and not withdrawn from the offer. Complete Genomics has roughly 34.3 million total shares outstanding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.